Rennova Health, Inc. · OTC:RNVA
Rennova Health — CollabRx — Merger or Acquisition (July 2015)
26 slides from Rennova Health's merger presentation, Jul 29, 2015
Slide 1: Investor Presentation (Pre-merger)
Investor Presentation (Pre-merger)
Slide 2: Safe Harbor
Safe Harbor This presentation includes forward-looking statements about CollabRx's and Medytox Solution’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations a
Slide 3: Participants in Solicitation and Additional Information
Participants in Solicitation and Additional Information CollabRx (NASDAQ: CLRX), Medytox (OTCQB: MMMS), and their respective directors, executive officers, and other employees may be deemed to be participants in the solicitation of proxies from CollabRx and Medytox stockholders with respect to the p
Slide 4: Overview of CollabRx
4 A leading provider of expert-informed clinical decision support systems for diagnostic labs, physicians and patients navigating advanced cancer. We address the emerging market for genomic testing in cancer with an industry-leading, scalable solution for evidence-based therapy selection related to
Slide 5: Overview of Medytox
A vertically-integrated provider of clinical laboratory testing and business solutions to drug rehab and pain management clinics and to private physician practices nationwide. Name Location Services Biohealth Medical Laboratory Miami, FL Screening and clinical International Technologies Waldwick, NJ
Slide 6: Rationale for the Merger - Strategic
Rationale for the Merger - Strategic 6 Strategic: adding to existing test menu, while building an end-to-end solution in cancer testing. Medytox plans to enter testing markets in clinical diagnostics, including cancer and diabetes.Opportunity exists to acquire a genomic testing lab or to develop one
Slide 7: Rationale for the Merger - Operational
Rationale for the Merger - Operational 7 Operational: offering centralized management and expertise for controlled growth and profit. Medytox maintains a corporate structure that includes key areas of expertise for health care companies, such as:Marketing and SalesComplianceLegalHIPAA-compliant ITDu
Slide 8: Rationale for the Merger - Financial
Rationale for the Merger - Financial 8 Financial: building a highly liquid platform on NASDAQ for a broader investor base and access to capital. Medytox has a strong base of revenue and profit in core business of toxicology testing.Medytox has a track record of on-boarding capabilities and expertise
Slide 9: Medytox History and Outlook
Medytox History and Outlook 9 Organic Growth and Diversification 2011 2012 2013 2014 2015
Slide 10: Medytox Integrated Solutions and Brands
Medytox Integrated Solutions and Brands 10 Value-added solutions support core lab service business and have independent operations and brands to pursue external growth. Our proprietary web-based ordering and reporting system Industry-leading solutions for Electronic Health Records Turnkey LIS for sm
Slide 11: Drug and Alcohol Rehab Market for Medytox
Drug and Alcohol Rehab Market for Medytox 11 Total Market Size – estimated at $35 Billion* Large and growing number of facilities in a fragmented market:Between 14,500 to 16,700 outpatient clinics*. Top 50 control less than 20% of the market*. Market growth from high demand:Over 23 million Americans
Slide 12: Chronic Pain Management Market for Medytox
Chronic Pain Management Market for Medytox 12 Total Market Size – estimated at $2-$4 billion*Large and growing number of clinics in a fragmented market*:Private clinics in the U.S. estimated between 1,500 to 2,500. More than 6,800 doctors specialize in pain management and more than 600,000 doctors a
Slide 13: Cancer Testing Market for CollabRx and Medytox
Cancer Testing Market for CollabRx and Medytox 13 Total Available Market – estimated at $14 billion* (12 million cancer patients in US)Current penetration for complex, multi-gene Next Generation Sequencing (NGS)-based tests – estimated at $1.3 billion**, including equipment sales.Major applications
Slide 14: End Market Drivers Favor Growth for Combined Company
End Market Drivers Favor Growth for Combined Company 14 Lab Services:Drivers are primarily secular growth and attention to physician - patient compliance.Largest growth markets for rehab centers are warm weather, coastal states of Florida and California.Physicians are under increasing scrutiny to en
Slide 15: Medytox Solutions Historic Financial Performance
Medytox Solutions Historic Financial Performance 15 (Dollars in Thousands) Annual Performance since Formation
Slide 16: Specialist Toxicology Testing Landscape
Specialist Toxicology Testing Landscape 16 Competitor Ownership Market Share (%) Toxicology Revenues 2014 (millions) 2014/2013 Revenue Growth Alere Toxicology Private 14% $331 (4-5%) Quest Diagnostics NYSE:DGX 9% $219 +4% Medytox Solutions OTCQB: MMMS 2% $58 +38% ALL OTHERS <75% $1,842 +7% AIT Labor
Slide 17: Near to mid-term Growth Strategy for Combined Company
Near to mid-term Growth Strategy for Combined Company 17 Continue to grow core lab business by offering high quality testing, a comprehensive menu, and superior customer service, supported by:Medytox Advantage™ – a proprietary web-based lab ordering and reporting software offering,a national presenc
Slide 18: Estimated Timeline for Merger and Rebranding
Estimated Timeline for Merger and Rebranding 18 July Oct August Sept At closing, the surviving listed entity will will be rebranded as: Rennova Health, Inc., NASDAQ: RNVA. NASDAQ Initial Listing Application and Qualification
Slide 19: NASDAQ Initial Listing Criteria
NASDAQ Initial Listing Criteria 19 Requirement Current Standard* Medytox CollabRx Stockholder’s equity $5 million ✔ Market value of publicly held shares $15 million ✔ Operating history 2 years ✔ Market value of listed securities $50 million ✔ Net Income from continuing operations $750 thousand ✔ Pub
Slide 20: Post-merger Management Team
Post-merger Management Team 20 Seamus Lagan, Chief Executive Officer. Directed the formation of Medytox and its transition from its former business via Alcimede, LLC, a consulting firm he founded in 2007 that specializes in restructuring, development and management of small companies in both the pri
Slide 21: Post-merger Management Team (continued)
Post-merger Management Team (continued) 21 Charles Darcy, Director: Compliance, Medytox Solutions, Inc. Served as COO at the Broward County Medical Examiner’s Office. Has over 30 years’ experience in the Health Care sector. Since 1988 is a licensed Laboratory supervisor in Florida. Bachelor’s in Cli
Slide 22: Post-merger Board of Directors
Post-merger Board of Directors 22 INSIDE DIRECTORS (2):Thomas R. Mika, Executive Chairman of Medytox (effective with the merger) and CEO, CollabRx, Inc., served from 2005 – 2012 as Chairman & CEO of Tegal Corporation and was its EVP/CFO since 2002. Extensive prior experience in executive management
Slide 23: Post-merger Board of Directors
Post-merger Board of Directors 23 Benjamin Frank, director of Medytox since 2013. Retired lawyer and businessman, with particular experience in healthcare, foreign trade, retail, business development and government. After practicing as an attorney, from 1962 to 1966, he was a Senior Vice President a
Slide 24: Summary Rationale for Merger
Summary Rationale for Merger 24 Medytox model for organic growth combined with diversification drives current and future company value.Track record of profitable growth and adherence with laws and regulations.Initial revenue diversification realized through sales by wholly-owned subsidiaries.Develop
Slide 25: Contacts
Contacts 25 Please contact the following individuals for additional information:Seamus Lagan, CEO – Medytox Solutions, Inc. slagan@medytoxsolutionsinc.comThomas Mika, CEO – CollabRx, Inc. tmika@collabrx.comInvestor and Public Relations:Sebastien Sainsbury, Medytox Solutions, Inc.ssainsbury@medytoxso
Slide 26: Company websites
www.medytoxsolutionsinc.comwww.collabrx.com 26